- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05469542
Everbeat Ring ECG Clinical Concordance Study
July 20, 2022 updated by: Grektek Inc.
Correlation of Electrocardiographic Signals Acquired by a Finger-worn ECG Sensor With a Standard 12-Lead ECG
This study is a cross-sectional observational study conducted in patients referred for routine ECG, to compare output from the everbeat finger-worn ECG device to standard of care (SOC) 12-lead electrocardiography.
No intervention is involved in this study.
Patients visiting the study site during the study period will be assessed for eligibility on a convenience basis, and observational data will be recorded on those eligible.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
65
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Brooklyn, New York, United States, 11217
- BKLYNCardio
-
Contact:
- Glenis Strachan, MD
- Phone Number: 718-237-4067
- Email: gasb@gmail.com
-
Principal Investigator:
- Charles Pollack, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients aged 18-90 presenting for a routine internal medicine or cardiology clinic visit
Description
Inclusion Criteria:
- Males or females aged 18 to 90 years.
- Under the care of a board-certified physician and referred for a routine electrocardiogram (ECG)
- Resting heart rate between 50 to 120 beats per minute (BPM).
Exclusion Criteria:
- Inability to wear the everbeat ring.
- Prior history of movement disorders including Parkinson's or benign tremors.
- Prior history of allergic skin reactions to metal including stainless steel.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
R-wave Amplitude
Time Frame: 50 days
|
R Peak Amplitude intraclass correlation coefficient between test and reference devices in mm
|
50 days
|
|
ST-segment
Time Frame: 50 Days
|
Concordance in ST-segment deviation from the TP segment if present in mm
|
50 Days
|
|
Blinded Cardiologist Review
Time Frame: 50 Days
|
Identify the first six consecutive distinct readable PQRST complexes without artifacts that match between the strips for evaluation.
Each reviewer will assign a pass/fail to the strips by visually assessing all 6 PQRST complexes.
A "pass" is given when the morphology of the PQRST complexes appears to overlay to the unaided eye.
A measurement of the R amplitude from the isoelectric baseline to the nearest millimeter for the first two QRS complexes in both the reference strip and everbeat strip.
The reviewers will be blinded to the identity of the reference strip and everbeat strip.
|
50 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
User acceptance survey
Time Frame: 50 days
|
To assess the ease of use of the everbeat ring in a random selection of users.
|
50 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 1, 2022
Primary Completion (Anticipated)
September 20, 2022
Study Completion (Anticipated)
September 20, 2022
Study Registration Dates
First Submitted
July 4, 2022
First Submitted That Met QC Criteria
July 20, 2022
First Posted (Actual)
July 21, 2022
Study Record Updates
Last Update Posted (Actual)
July 21, 2022
Last Update Submitted That Met QC Criteria
July 20, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00064656
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.